EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Viracta Therapeutics's Enterprise Value is $16.56 Mil.
Viracta Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-36.40 Mil. Therefore, Viracta Therapeutics's EV-to-FCF for today is -0.45.
The historical rank and industry rank for Viracta Therapeutics's EV-to-FCF or its related term are showing as below:
VIRX'
s EV-to-FCF Range Over the Past 10 Years
Min: -52.09 Med: 0 Max: 1.01
Current: -0.49
During the past 4 years, the highest EV-to-FCF of Viracta Therapeutics was 1.01. The lowest was -52.09. And the median was 0.00.
VIRX's EV-to-FCF is ranked worse than 100% of 381
companies
in the Biotechnology industry
Industry Median: 7.68
vs VIRX: -0.49
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Viracta Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Viracta Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Viracta Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viracta Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Viracta Therapeutics's EV-to-FCF falls into.
Viracta Therapeutics's current Enterprise Value is $16.56 Mil.
Viracta Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Viracta Therapeutics's PE Ratio for today is calculated as:
Viracta Therapeutics's share price for today is $0.8399.
Viracta Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.230.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Viracta Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Viracta Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Viracta Therapeutics (Viracta Therapeutics) Business Description
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VIRX has been successfully added to your 